Frequency of Any New-onset Chronic Medical Conditions (NOCMCs);Frequency of Any Protocol Specified Adverse Events of Special Interest (AESIs);Frequency of Any Serious Adverse Events (SAEs);Frequency of Any Unsolicited Adverse Events (AEs);Frequency of Local Solicited Reactogenicity Adverse Events (AEs);Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs);Geometric Mean AUC of Antibody Against B.1.1.529 S2-P for Cohort 1;Geometric Mean AUC of Antibody Against B.1.617.2 S2-P for Cohort 1;Geometric Mean AUC of Antibody Against BA.1 S2-P for Cohort 2;Geometric Mean AUC of Antibody Against BA.5 S2-P for Cohort 2;Geometric Mean AUC of Antibody of Antibody Against WA-1 S2-P for Cohort 2;Geometric Mean of Area Under the Curve (AUC) of Antibody Against WA-1 S2-P for Cohort 1;Geometric Mean of AUC of Antibody Against B.1.351 S2-P for Cohort 1;Geometric Mean of Pseudovirus Neutralization Against B.1.1.529 for Cohort 1;Geometric Mean of Pseudovirus Neutralization Against B.1.351 for Cohort 1;Geometric Mean of Pseudovirus Neutralization Against B.1.617.2 for Cohort 1;Geometric Mean of Pseudovirus Neutralization Against BA.1 for Cohort 2;Geometric Mean of Pseudovirus Neutralization Against BA.4/5 for Cohort 2;Geometric Mean of Pseudovirus Neutralization Against D614G for Cohort 1;Geometric Mean of Pseudovirus Neutralization Against D614G for Cohort 2;Geometric Mean of Pseudovirus Neutralization Against XBB.1 for Cohort 2;Number of Participants With Any Medically-attended Adverse Events (MAAEs);Percent of Participants Who Seroconverted Against B.1.1.529 for Cohort 1;Percent of Participants Who Seroconverted Against B.1.1.529 S2-P for Cohort 1;Percent of Participants Who Seroconverted Against B.1.351 for Cohort 1;Percent of Participants Who Seroconverted Against B.1.351 S2-P for Cohort 1;Percent of Participants Who Seroconverted Against B.1.617.2 for Cohort 1;Percent of Participants Who Seroconverted Against B.1.617.2 S2-P for Cohort 1;Percent of Participants Who Seroconverted Against BA.1 for Cohort 2;Percent of Participants Who Seroconverted Against BA.1 for Cohort 2;Percent of Participants Who Seroconverted Against BA.1 S2-P for Cohort 2;Percent of Participants Who Seroconverted Against BA.4/5 for Cohort 2;Percent of Participants Who Seroconverted Against BA.4/5 for Cohort 2;Percent of Participants Who Seroconverted Against BA.5 S2-P for Cohort 2;Percent of Participants Who Seroconverted Against D614G for Cohort 1;Percent of Participants Who Seroconverted Against D614G for Cohort 2;Percent of Participants Who Seroconverted Against D614G for Cohort 2;Percent of Participants Who Seroconverted Against WA-1 S2-P for Cohort 1;Percent of Participants Who Seroconverted Against WA-1 S2-P for Cohort 2;Percent of Participants Who Seroconverted Against XBB.1 for Cohort 2;Percent of Participants Who Seroconverted Against XBB.1 for Cohort 2

Frequency of Any New-onset Chronic Medical Conditions (NOCMCs);Frequency of Any Protocol Specified Adverse Events of Special Interest (AESIs);Frequency of Any Serious Adverse Events (SAEs);Frequency of Any Unsolicited Adverse Events (AEs);Frequency of Local Solicited Reactogenicity Adverse Events (AEs);Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs);Geometric Mean AUC of Antibody Against B.1.1.529 S2-P for Cohort 1;Geometric Mean AUC of Antibody Against B.1.617.2 S2-P for Cohort 1;Geometric Mean AUC of Antibody Against BA.1 S2-P for Cohort 2;Geometric Mean AUC of Antibody Against BA.5 S2-P for Cohort 2;Geometric Mean AUC of Antibody of Antibody Against WA-1 S2-P for Cohort 2;Geometric Mean of Area Under the Curve (AUC) of Antibody Against WA-1 S2-P for Cohort 1;Geometric Mean of AUC of Antibody Against B.1.351 S2-P for Cohort 1;Geometric Mean of Pseudovirus Neutralization Against B.1.1.529 for Cohort 1;Geometric Mean of Pseudovirus Neutralization Against B.1.351 for Cohort 1;Geometric Mean of Pseudovirus Neutralization Against B.1.617.2 for Cohort 1;Geometric Mean of Pseudovirus Neutralization Against BA.1 for Cohort 2;Geometric Mean of Pseudovirus Neutralization Against BA.4/5 for Cohort 2;Geometric Mean of Pseudovirus Neutralization Against D614G for Cohort 1;Geometric Mean of Pseudovirus Neutralization Against D614G for Cohort 2;Geometric Mean of Pseudovirus Neutralization Against XBB.1 for Cohort 2;Number of Participants With Any Medically-attended Adverse Events (MAAEs);Percent of Participants Who Seroconverted Against B.1.1.529 for Cohort 1;Percent of Participants Who Seroconverted Against B.1.1.529 S2-P for Cohort 1;Percent of Participants Who Seroconverted Against B.1.351 for Cohort 1;Percent of Participants Who Seroconverted Against B.1.351 S2-P for Cohort 1;Percent of Participants Who Seroconverted Against B.1.617.2 for Cohort 1;Percent of Participants Who Seroconverted Against B.1.617.2 S2-P for Cohort 1;Percent of Participants Who Seroconverted Against BA.1 for Cohort 2;Percent of Participants Who Seroconverted Against BA.1 for Cohort 2;Percent of Participants Who Seroconverted Against BA.1 S2-P for Cohort 2;Percent of Participants Who Seroconverted Against BA.4/5 for Cohort 2;Percent of Participants Who Seroconverted Against BA.4/5 for Cohort 2;Percent of Participants Who Seroconverted Against BA.5 S2-P for Cohort 2;Percent of Participants Who Seroconverted Against D614G for Cohort 1;Percent of Participants Who Seroconverted Against D614G for Cohort 2;Percent of Participants Who Seroconverted Against D614G for Cohort 2;Percent of Participants Who Seroconverted Against WA-1 S2-P for Cohort 1;Percent of Participants Who Seroconverted Against WA-1 S2-P for Cohort 2;Percent of Participants Who Seroconverted Against XBB.1 for Cohort 2;Percent of Participants Who Seroconverted Against XBB.1 for Cohort 2

Magnitude of SARS-CoV-2 specific antibody binding and neutralization titers;Occurrence of adverse events (AEs);Occurrence of Adverse Events of Special Interest (AESIs).;Occurrence of New-Onset Chronic Medical Condition (NOCMCs).;Occurrence of Related Medically attended adverse events (MAAEs).;Occurrence of Serious Adverse Events (SAEs).;Occurrence of solicited reactogenicity adverse events (AEs);Occurrence of solicited reactogenicity adverse events (AEs);Response rate of SARS-CoV-2 specific antibody binding and neutralization titers

Magnitude of SARS-CoV-2 specific antibody binding and neutralization titers;Occurrence of adverse events (AEs);Occurrence of Adverse Events of Special Interest (AESIs).;Occurrence of New-Onset Chronic Medical Condition (NOCMCs).;Occurrence of Related Medically attended adverse events (MAAEs).;Occurrence of Serious Adverse Events (SAEs).;Occurrence of solicited reactogenicity adverse events (AEs);Occurrence of solicited reactogenicity adverse events (AEs);Response rate of SARS-CoV-2 specific antibody binding and neutralization titers

Magnitude of SARS-CoV-2 specific antibody binding and neutralization titers;Occurrence of adverse events (AEs);Occurrence of Adverse Events of Special Interest (AESIs).;Occurrence of New-Onset Chronic Medical Condition (NOCMCs).;Occurrence of Related Medically attended adverse events (MAAEs).;Occurrence of Serious Adverse Events (SAEs).;Occurrence of solicited reactogenicity adverse events (AEs);Response rate of SARS-CoV-2 specific antibody binding and neutralization titers

Magnitude of SARS-CoV-2 specific antibody binding and neutralization titers;Occurrence of adverse events (AEs);Occurrence of Adverse Events of Special Interest (AESIs).;Occurrence of New-Onset Chronic Medical Condition (NOCMCs).;Occurrence of Related Medically attended adverse events (MAAEs).;Occurrence of Serious Adverse Events (SAEs).;Occurrence of solicited reactogenicity adverse events (AEs);Response rate of SARS-CoV-2 specific antibody binding and neutralization titers

Magnitude of SARS-CoV-2 specific antibody binding and neutralization titers;Occurrence of Adverse Events (AEs) following delayed booster vaccination;Occurrence of Adverse Events of Special Interest (AESIs) after last dose on study.;Occurrence of local solicited reactogenicity adverse events (AEs);Occurrence of Related Medically attended adverse events (MAAEs) after last dose on study.;Occurrence of Serious Adverse Event (SAEs) after last dose on study.;Response rate of SARS-CoV-2 specific antibody binding and neutralization titers

Magnitude of SARS-CoV-2 specific antibody binding and neutralization titers;Occurrence of Adverse Events (AEs) following delayed booster vaccination;Occurrence of Adverse Events of Special Interest (AESIs) after last dose on study.;Occurrence of local solicited reactogenicity adverse events (AEs);Occurrence of Related Medically attended adverse events (MAAEs) after last dose on study.;Occurrence of Serious Adverse Event (SAEs) after last dose on study.;Response rate of SARS-CoV-2 specific antibody binding and neutralization titers